Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Ensereptide (PXL01) is a synthetic peptide derived from human lactoferrin, an iron-binding glycoprotein found in milk and mucosal secretions. It is being developed primarily for the prevention of post-surgical adhesions, particularly after tendon repair surgery in the hand, and for the prevention of dermal scarring after surgery or trauma. The drug acts through several mechanisms including immunomodulation—by inhibiting pro-inflammatory cytokines such as IL-1β, IL-6, IL-8, and TNF-α—and enhancement of fibrinolytic activity by inhibiting plasminogen activator inhibitor-1 (PAI-1). These actions reduce inflammation and promote fibrinolysis at surgical sites to prevent adhesion formation and scar tissue development. Ensereptide is typically formulated with sodium hyaluronate as a carrier to provide local delivery and sustained release at the site of injury[1][3][4][5][7].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on ensereptide.